Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up

Annals of Oncology

Volumn 14, Issue 2, 2003, Pages 268-272

  Canellos, G P ^a   Gollub, J ^b   Neuberg, D ^a   Mauch, P ^c   Shulman, L N ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

EVA; Hodgkin's disease chemotherapy

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; COLONY STIMULATING FACTOR; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ALLERGIC REACTION; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LONG TERM CARE; LUNG DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM TUMOR; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR DISEASE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VINBLASTINE;

EID: 0344837929     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg076     Document Type: Article

References (28)

1. Somers R, Cardé P, Henry-Amar M et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279-287.
2. Viviani SM, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996; 14: 1421-1430.
3. Connors JM, Klimo P, Adams G et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 1638-1645.
4. Gobbi PG, Pieresca C, Ghirardelli ML et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 1998; 91: 2704-2712.
5. Glick JH, Young ML, Harrington D et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the Intergroup trial. J Clin Oncol 1998; 16: 19-26.
6. Montoto S, Camos M, López-Guillermo A et al. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin's disease. Cancer 2000; 88: 2142-2148.
7. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
8. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996; 6: 225-242.
9. Viviani S, Santoro A, Ragni G et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21: 601-605.
10. Kulkarni SS, Sastry PSRK, Saikia TK et al. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol 1997; 20: 354-357.
11. Duggan D, Petroni G, Johnson J et al. MOPP/ABV versus ABVD for advanced Hodgkin's disease-a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 1997; 16: 12a (Abstr 43).
12. Hirsch A, Vander Els N, Straus DJ et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14: 1297-1305.
13. Horning SJ, Adhikari A, Rizk N et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 1994; 12: 297-305.
14. Taylor RE, McElwain TJ, Barrett A, Peckham MJ. Etoposide as a single agent in relapsed advanced lymphomas. A phase II study. Cancer Chemother Pharmacol 1982; 7: 175-177.
15. Kirshner JJ, Anderson JR, Parker B et al. Etoposide in combination as first-line chemotherapy for advanced Hodgkin's disease. Cancer 1993; 71: 1852-1856.
16. Canellos GP, Petroni GR, Barcos M et al. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. J Clin Oncol 1995; 13: 2005-2011.
17. McElwain TJ, Toy J, Smith E. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer 1977; 36: 276-280.
18. Druker BJ, Rosenthal DS, Canellos GP. Chlorambucil, vinblastine, procarbazine, and prednisone-an effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease. Cancer 1989; 63: 1060-1064.
19. Santoro A, Bonadonna G, Valagussa P et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
20. Andrieu J-M, Jais J-P, Colonna P et al. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages. Ann Oncol 1998; 9: 195-203.
21. Zinzani PL, Magagnoli M, Frezza G et al. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease. Leuk Lymphoma 1999; 32: 553-559.
22. Smith MA, Rubeinstein L, Anderson JR et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999; 17: 569-577.
23. Richards MA, Waxman JH, Man T et al. EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemother Pharmacol 1986; 18: 51-53.
24. Brizel DM, Gockerman JP, Crawford J et al. A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease. Cancer 1994; 74: 159-163.
25. Radford JA, Crowther D, Rohatiner AZS et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13: 2379-2385.
26. Sureda A, Arranz R, Iriondo A et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395-1404.
27. Lazarus HM, Loberiza FR Jr, Zhang M-J et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplantation 2001; 27: 387-396.
28. Fermé C, Mounier N, Divine M et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Études des Lymphomes de l'Adulte H89 trial. J Clin Oncol 2002; 20: 467-475.